Jeffrey S. Heier, MD, of Ophthalmic Consultants of Boston, and Daniel Roth, MD, of Retina Vitreous Center in New Jersey are joining the board, which assists in advancing Ohr’s Squalamine eye drop program through clinical efficacy trials.
“We are delighted to be working with thought leaders in the retina community of the caliber of Drs. Heier and Roth,” said Irach B. Taraporewala, PhD, CEO of Ohr Pharmaceutical, in the release. “The reaction of the retinal physician community to our ongoing phase II Squalamine eye drop clinical trial has been very enthusiastic. We will continue to utilize our distinguished scientific advisory board to further expand into additional neovascular ophthalmic indications.”
OHR Pharmaceutical is headquartered in New York.
Related Articles on Ophthalmology:
Bascom Palmer Eye Institute to Expand FL Center in Naples
Study: Drainage Device May Replace Eye Drops for Some Glaucoma Patients
UAB Launches CDC-Funded Glaucoma Detection Program
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
